ARDS Clinical Trial
— OCTANEOfficial title:
Occlusion Pressure at 100 Msec, TCe ( Expiratory Time Constant ), Stress Energy Density, Mechanical Power, Ventilatory Ratio and C20/Cdyn in Predicting Outcomes in Patients With Moderately Severe ARDS, Who Are on Mechanical Ventilation
NCT number | NCT06400095 |
Other study ID # | RAMOCTANE |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2023 |
Est. completion date | July 2024 |
This is a single-centre prospective observational study aimed to determine if Pocc (occlusion pressure at 100 msec), TCe ( Expiratory time constant ), Mechanical Stress power, Ventilatory ratio and C20/Cdyn would predict outcomes in patients with moderately severe ARDS (Acute respiratory distress syndrome), who are on mechanical ventilation
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients with Acute respiratory failure needing mechanical ventilation - Diagnosis of Severe ARDS with severity: PF ratio < 150, with PEEP/CPAP > 5 Exclusion Criteria: - r2 < 0.95, monitored on the ventilator - Expiratory flow that is not first-order or non-exponential decay - Patients with Nor-epinephrine requirements > 0.1 mcg/kg/min within 2 hours of intubation - Patients requiring ECMO ( Extracorporeal membrane oxygenation) - Patients with COPD or pulmonary fibrosis with a premorbid FEV1 < 1.5 L - Severe atherosclerotic vascular disease - Patients with a chest tube, intra-abdominal hypertension or with its risk factors - Patients with structural heart disease including pulmonary hypertension (RVSP > 45) and heart failure - All comfort care orders in the ICU - Patients who underwent tracheostomy |
Country | Name | City | State |
---|---|---|---|
United States | St Cloud Hospital | Saint Cloud | Minnesota |
Lead Sponsor | Collaborator |
---|---|
CentraCare |
United States,
Guttmann J, Eberhard L, Fabry B, Bertschmann W, Zeravik J, Adolph M, Eckart J, Wolff G. Time constant/volume relationship of passive expiration in mechanically ventilated ARDS patients. Eur Respir J. 1995 Jan;8(1):114-20. doi: 10.1183/09031936.95.08010114. — View Citation
Paudel R, Trinkle CA, Waters CM, Robinson LE, Cassity E, Sturgill JL, Broaddus R, Morris PE. Mechanical Power: A New Concept in Mechanical Ventilation. Am J Med Sci. 2021 Dec;362(6):537-545. doi: 10.1016/j.amjms.2021.09.004. Epub 2021 Sep 28. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival or mortality | We will assess whether the patient would survive or not | From the date of enrollment to 90 days from enrolment or date of death, whichever came first, assessed up to 90 days. | |
Secondary | MAKE ( Major adverse kidney events) | Will assess the need for dialysis or any evidence of acute kidney injury | From the date of enrollment to 90 days from enrolment or date of death, whichever came first, assessed up to 90 days. | |
Secondary | ICU and Hospital length of stay | we shall assess the duration of patients stay in the ICU and in the hospital | From the date of enrollment to the number of days in ICU and in the hospital until discharge or date of death whichever came first, assessed up to 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435613 -
Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients
|
N/A | |
Enrolling by invitation |
NCT05020210 -
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
|
||
Completed |
NCT04468971 -
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
|
Phase 1 | |
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04493242 -
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
|
Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT01949272 -
Optimization of PEEP for Alveolar Recruitment in ARDS
|
N/A | |
Not yet recruiting |
NCT01668368 -
Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance
|
N/A | |
Completed |
NCT01881061 -
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit
|
N/A | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Recruiting |
NCT04764032 -
Right Ventricular Dysfunction in Ventilated Patients With COVID-19
|
||
Completed |
NCT04556513 -
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
|
||
Recruiting |
NCT06036056 -
NMR Based Metabolomics Kinetics in ARDS Patients
|
||
Recruiting |
NCT04503876 -
Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT04643691 -
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Not yet recruiting |
NCT05341687 -
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
|
||
Recruiting |
NCT05056090 -
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
|
N/A |